<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656394</url>
  </required_header>
  <id_info>
    <org_study_id>GL-1</org_study_id>
    <nct_id>NCT02656394</nct_id>
  </id_info>
  <brief_title>Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101</brief_title>
  <official_title>Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glia, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glia, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28&#xD;
      days in ameliorating adverse ocular side effects in patients under ongoing treatment with&#xD;
      glaucoma medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to assess the safety and efficacy of a new treatment for ocular surface disease&#xD;
      associated with the use of glaucoma medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 22, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glaucoma medication ocular side effect symptoms</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Glaucoma medication ocular side effect symptoms:&#xD;
Ocular discomfort&#xD;
Burning&#xD;
Stinging&#xD;
Conjunctival redness&#xD;
Itching&#xD;
Dryness&#xD;
Foreign object sensation&#xD;
Grittiness&#xD;
Pain&#xD;
Eyelid swelling&#xD;
Eyelid redness&#xD;
Photophobia&#xD;
Excessive tearing&#xD;
Crusty lids&#xD;
Blurred vision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucoma medication ocular side effect signs</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Glaucoma medication ocular side effect signs:&#xD;
Tearscope tear film examination&#xD;
Tear meniscus height (TMH)&#xD;
Tear film break up time (NIKBUT)&#xD;
Bulbar redness (BR)&#xD;
Meibography&#xD;
Conjunctival redness (hyperemia)&#xD;
Blepharitis&#xD;
Lid margin vessel inflammation&#xD;
Punctate keratitis&#xD;
Corneal staining&#xD;
Conjunctival staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other signs</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Other signs:&#xD;
Visual acuity&#xD;
Intraocular pressure&#xD;
Artificial tear use&#xD;
Glaucoma medication compliance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Adverse events:&#xD;
Visual acuity&#xD;
Slit lamp biomicroscopy&#xD;
Undilated fundoscopy examination&#xD;
Intraocular pressure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Ocular Surface Disease</condition>
  <arm_group>
    <arm_group_label>GL101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GL101 topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo topical gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GL101</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>GL101</arm_group_label>
    <other_name>Pro-Ocular</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical gel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of any race, at least 18 years of age at Visit 1 Screening.&#xD;
&#xD;
          2. Has provided verbal and written informed consent.&#xD;
&#xD;
          3. Be able and willing to follow instructions, including participation in all study&#xD;
             assessments and visits.&#xD;
&#xD;
          4. Currently being treated for glaucoma using at least two medications, and be willing to&#xD;
             continue on the same regime.&#xD;
&#xD;
          5. Suffers from at least two of the symptoms in the GLIA™ Glaucoma Medication Ocular Side&#xD;
             Effect Symptoms Questionnaire at a severity of 2 (moderate) or more.&#xD;
&#xD;
          6. If a woman of childbearing potential, have a negative urine pregnancy test at Visit 1&#xD;
             and be using an adequate method of birth control throughout the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Comorbidity with other severe or chronic eye conditions that in the judgment of the&#xD;
             investigator will interfere with study assessments, such as corneal opacities and&#xD;
             scars, dystrophies, epithelial scarring, infections, blood clots, etc.&#xD;
&#xD;
          2. Best corrected visual acuity (BCVA) at baseline &lt;20/200.&#xD;
&#xD;
          3. Has a condition or history that, in the opinion of the investigator, may interfere&#xD;
             significantly with the subject's participation in the study.&#xD;
&#xD;
          4. A woman who is pregnant, nursing an infant, or planning a pregnancy.&#xD;
&#xD;
          5. Has a known adverse reaction and/or sensitivity to the study drug or its components.&#xD;
&#xD;
          6. Routine use (more than twice a week) of a chlorinated swimming pool.&#xD;
&#xD;
          7. Unwilling or unable to cease using the following medications during the study period:&#xD;
             Topical ocular cyclosporine (e.g. Restasis®), anti-histamines, antipsychotics, or eye&#xD;
             gels.&#xD;
&#xD;
          8. Currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 30 days prior to Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ritch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Eye &amp; Ear Infirmary of Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Eye &amp; Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ocular surface disease</keyword>
  <keyword>glaucoma medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

